Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Angela Storka is active.

Publication


Featured researches published by Angela Storka.


Cardiovascular Research | 2010

Primary sources and immunological prerequisites for sST2 secretion in humans

Michael Mildner; Angela Storka; Michael Lichtenauer; Veronika Mlitz; Minoo Ghannadan; Konrad Hoetzenecker; Stefanie Nickl; Balazs Dome; Erwin Tschachler; Hendrik Jan Ankersmit

AIMS Serum levels of the soluble growth stimulation gene-2 (sST2) are elevated in heart and pulmonary diseases. However, the relationship of the sST2/interleukin (IL)-33 axis and its triggers as well as its organ distribution is still not known. This study was thus designed to investigate the cellular origin and regulation of sST2 and IL-33 in vitro and in vivo. METHODS AND RESULTS sST2 and IL-33 gene expression and protein secretion were analysed in pooled organ-specific cDNAs and in primary cell cultures, respectively, by RT-PCR and ELISA technology. The strongest sST2 mRNA expression was detected in heart and lung tissues, which correlated with spontaneous secretion of sST2 protein in vitro. The inflammatory cytokines IL-1alpha, IL-1beta, and tumour necrosis factor alpha as well as supernatants of lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells led to an enhanced secretion of sST2 in cultured cardiac myocytes and lung alveolar epithelial cells. These cytokines enhanced sST2 secretion via an NFkappaB-dependent mechanism. In addition, LPS stimulation in humans in vivo induced a short-term inflammatory response that was followed by a massive enhancement of sST2 secretion. CONCLUSION These results identify the primary sources and inflammatory triggers for the enhancement of sST2 secretion and demonstrate a relationship between inflammation and the secretion of a bioactive member of the IL-1R family, both in vitro and in vivo.


European Journal of Clinical Investigation | 2008

Angiotensin inhibition stimulates PPARγ and the release of visfatin

Angela Storka; E. Vojtassakova; M. Mueller; Stylianos Kapiotis; Dominik G. Haider; A. Jungbauer; Michael Wolzt

Background  Angiotensin converting enzyme inhibitors (ACE‐I) and angiotensin receptor blockers (ARB) exhibit beneficial antidiabetic effects in patients with type 2 diabetes independent of their blood pressure‐lowering effects. Some antidiabetic properties of ARB and ACE‐I might by exerted by activation of peroxisome proliferator‐activated receptor gamma (PPARγ). However, it is not clear whether this action is drug specific.


principles and practice of constraint programming | 2015

Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans.

Angela Storka; Brigitta Vcelar; Uros Klickovic; Ghazaleh Gouya; Stefan Weisshaar; Stefan Aschauer; Gordon Bolger; Lawrence Helson; Michael Wolzt

INTRODUCTION Experimental studies have shown that liposomal curcumin can exert a reduction in tumor growth in pancreatic and colorectal cancer. In this phase I clinical trial we investigated the pharmacokinetics, safety, and tolerability of intravenously administered liposomal curcumin in healthy subjects. MATERIAL AND METHODS 50 male and female participants were included in this randomized, placebo-controlled double-blind phase I dose escalation study. Subjects received a single dose of liposomal curcumin (10 - 400 mg/m2; n = 2 - 6 per group) or placebo over 2 hours intravenously. RESULTS Dose-dependent increases in the plasma concentrations of curcumin and its metabolite tetrahydrocurcumin (THC) were detected. After the end of drug infusion, curcumin and THC plasma concentrations decreased within 6 - 60 minutes below the limit of quantification. Mean urinary excretion was ~ 0.1% of total systemic clearance. Liposomal curcumin was tolerated well, but a transient red blood cell echinocyte formation with concomitant increase in mean cellular volume was observed at dosages ≥ 120 mg/m2. CONCLUSION Short-term intravenous dosing of liposomal curcumin appears to be safe up to a dose of 120 mg/m2. Changes in red blood cell morphology may represent a dose limiting sign of toxicity.


European Journal of Clinical Investigation | 2014

Association of endostatin with mortality in patients with chronic heart failure.

Ghazaleh Gouya; Jolanta M. Siller-Matula; Monika Fritzer-Szekeres; Stephanie Neuhold; Angela Storka; Lisa M. Neuhofer; Martin Clodi; Martin Hülsmann; Richard Pacher; Michael Wolzt

Experimental data imply that in decompensated heart failure (HF), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF patients.


BioMed Research International | 2014

Human Pharmacokinetics of High Dose Oral Curcumin and Its Effect on Heme Oxygenase-1 Expression in Healthy Male Subjects

Uros Klickovic; Daniel Doberer; Ghazaleh Gouya; Stefan Aschauer; Stefan Weisshaar; Angela Storka; Martin Bilban; Michael Wolzt

Purpose. Heme oxygenase-1 (HO-1) has been proposed to exert pharmacological benefits by its antioxidative and anti-inflammatory effects. HO-1 expression may be affected by the GT length polymorphism in the promoter region of the HO-1 gene. We investigated the inducibility of HO-1 by orally administered curcumin in healthy male subjects and its correlation with the GT length polymorphism. Methods. In an open label uncontrolled phase-1 pilot study, ten male subjects received 12 g of oral curcumin. To investigate the effects of the GT length polymorphism on the inducibility of HO-1, five subjects with homozygous short and five with homozygous long GT genotypes were studied. Plasma concentrations of curcumin, bilirubin, HO-1 mRNA, and protein expression in peripheral blood mononuclear cells (PBMCs) were analyzed over 48 hours. Results. At a detection limit of 1 µg/mL curcumin could not be detected in plasma of any subject. Compared to baseline, HO-1 mRNA and protein levels were not induced in PBMCs at any time point up to 48 hours. There was no correlation between any of the parameters and GT length polymorphism. Conclusions. Oral curcumin administration has low bioavailability and does not induce HO-1 on mRNA or protein level in PBMCs.


Peptides | 2010

Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.

Bernhard Burian; Angela Storka; Beatrice A. Marzluf; Yong-Cheng Yen; Christopher Lambers; Bruno Robibaro; Karin Vonbank; Wilhelm Mosgoeller; Ventzislav Petkov

Vasoactive intestinal peptide (VIP) is one of the most abundant molecules found in the respiratory tract. Due to its anti-inflammatory and bronchodilatatory properties, it has been proposed as a novel treatment for chronic obstructive pulmonary disease (COPD). The actions of VIP are mediated via three different G-protein-coupled receptors (VPAC1, VPAC2 and PAC1) which are expressed in the respiratory tract and on immunocompetent cells including macrophages. Alveolar macrophages (AM) are key players in the pathogenesis of COPD and contribute to the severity and progression of the disease. While VPAC1 has been reported to be elevated in subepithelial cells in smokers with chronic bronchitis, little is known about VPAC expression of AM in COPD patients. AM from COPD patients show a strong VPAC1 expression which exceeds VPAC2. A similar receptor expression pattern was also observed in lipopolysaccharide (LPS)-activated monocyte-derived macrophages (MDM) from healthy volunteers and COPD patients. VIP has been shown to down-regulate interleukin 8 (IL-8) secretion significantly in MDM after LPS stimulation. The response to VIP was similar in MDM from COPD patients and healthy volunteers. Our results indicate that VPAC1 up-regulation in macrophages is a common mechanism in response to acute and chronic pro-inflammatory stimuli. Although VPAC1 up-regulation is dominant, both receptor subtypes are necessary for optimal anti-inflammatory signaling. The high VPAC1 expression in AM may reflect the chronic pro-inflammatory environment found in the lung of COPD patients. Treatment with VIP may help to decrease the chronic inflammation in the lung of COPD patients.


Vascular Pharmacology | 2014

Effect of systemic high dose vitamin C therapy on forearm blood flow reactivity during endotoxemia in healthy human subjects

Stefan Aschauer; Ghazaleh Gouya; Uros Klickovic; Angela Storka; Stefan Weisshaar; C. Vollbracht; B. Krick; G. Weiss; Michael Wolzt

OBJECTIVE Acute inflammation induced by administration of Escherichia coli lipopolysaccharide endotoxin (LPS) reduces plasma concentrations of vitamin C and impairs vascular endothelium-derived nitric oxide (NO) bioactivity. We tested the hypothesis that systemically administered high dose vitamin C restores the endogenous anti-oxidant potential and improves NO-dependent vasodilatation in the forearm vasculature. DESIGN & SETTING 36 male subjects were enrolled in this balanced, placebo controlled cross-over study. Forearm blood flow (FBF) reactivity to acetylcholine (ACh) and glyceryl-trinitrate (GTN), a sensitive test for endothelial function, was assessed at baseline and 4h after LPS-administration (20 IU/kg i.v). The effect of two different doses of intravenous vitamin C (Vitamin C-Injektopas®), 320 mg/kg and 480 mg/kg over 2h, or placebo on forearm vascular function was studied after LPS. MAIN RESULTS LPS caused transient flu-like symptoms, decreased plasma vitamin C concentrations and reduced the ACh-dependent increase in FBF by up to 76%. Vitamin C at a mean plasma concentration of 3.2 or 4.9 mmol/L restored the response to ACh compared to baseline. CONCLUSION High dose systemic vitamin C recovers LPS-induced endothelium-dependent vasodilation in the forearm resistance vasculature. This provides a rationale for a further clinical study of the systemic vitamin C effect under inflammatory conditions.


Clinical Endocrinology | 2009

Adipokines in type 1 diabetes after successful pancreas transplantation: normal visfatin and retinol-binding-protein-4, but increased total adiponectin fasting concentrations

Marietta Stadler; Angela Storka; Eva Anna Theuer; Michael Krebs; Elena Vojtassakova; Peter Nowotny; Giovanni Pacini; Thomas Kästenbauer; Anton Luger; Rudolf Prager; Michael Wolzt; Christian Anderwald

Objective  In type 1 diabetes mellitus (T1DM), the release of many hormones, not only from beta‐cells, but also from adipocytes (adipokines) may be altered. After successful pancreas–kidney‐transplantation (PKTx), T1DM patients can revert to a nondiabetic metabolism, but it is unclear whether alterations of adipokines are still present after PKTx.


Mediators of Inflammation | 2013

E. coli endotoxin modulates the expression of Sirtuin proteins in PBMC in humans.

Angela Storka; Gerhard Führlinger; Martin Seper; Lisa Wang; Michael Jew; Asha Leisser; Michael Wolzt

Background. Sirtuin (SIRT) proteins are class I histone deacetylases displaying gene regulatory functions in inflammatory, cancer, and metabolic diseases. These SIRT actions involve the nuclear factor κB and its inhibitor IκB pathway. However, the regulation of SIRT in vivo is still unclear. Material and Methods. In a human endotoxemia model, 20 healthy male subjects received an intravenous bolus of 2 ng/kg body weight Escherichia coli endotoxin (LPS). SIRT expression was investigated in peripheral blood mononuclear cells (PBMC) with qPCR and Western blot before and 3 hours, 6 hours, and 24 hours after LPS challenge. Additionally, SIRT regulation was studied in vitro in cultivated PBMC after incubation with 20 ng/mL LPS. Results. A downregulation by >40% of SIRT1 mRNA was detectable 3 hours after LPS and of SIRT3 mRNA 6 hours after LPS. SIRT3, IκBα, and IκB-β protein expressions were decreased 3 and 6 hours after LPS. SIRT2 mRNA or protein expression did not change following LPS. These findings were consistent in vitro and associated with augmented phosphorylation of IκB-β. Discussion. In this E. coli endotoxemia model, SIRT1 and SIRT3 mRNA expressions in PBMC in humans were reduced after LPS challenge. This suggests that SIRT may represent an inflammatory target protein in vivo.


Clinical Endocrinology | 2010

Adipokines in type 1 diabetes after successful pancreas transplantation

Marietta Stadler; Angela Storka; Eva Anna Theuer; Michael Krebs; Elena Vojtassakova; Peter Nowotny; Giovanni Pacini; Thomas Kästenbauer; Anton Luger; Rudolf Prager; Michael Wolzt; Christian Anderwald

Objective  In type 1 diabetes mellitus (T1DM), the release of many hormones, not only from beta‐cells, but also from adipocytes (adipokines) may be altered. After successful pancreas–kidney‐transplantation (PKTx), T1DM patients can revert to a nondiabetic metabolism, but it is unclear whether alterations of adipokines are still present after PKTx.

Collaboration


Dive into the Angela Storka's collaboration.

Top Co-Authors

Avatar

Michael Wolzt

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Ghazaleh Gouya

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Giovanni Pacini

National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stefan Aschauer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Stefan Weisshaar

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Uros Klickovic

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anton Luger

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Gerhard Führlinger

Medical University of Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge